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Abstract
Reliable measurement of clinically relevant autoimmune antibodies toward phospholipid-
protein conjugates is highly desirable in research and clinical assays. To date, the develop-
ment in this field has been limited to the use of natural heterogeneous antigens. However,
this approach does not take structural features of biologically active antigens into account
and leads to low reliability and poor scientific test value. Here we describe novel phospho-
lipid-protein conjugates for specific detection of human autoimmune antibodies. Our syn-
thetic approach includes mild oxidation of synthetic phospholipid cardiolipin, and as the last
step, coupling of the product with azide-containing linker and copper-catalyzed click chem-
istry with β2-glycoprotein I and prothrombin. To prove utility of the product antigens, we
used enzyme-linked immunosorbent assay and three cohorts of samples obtained from
patients in Denmark (n = 34) and the USA (n = 27 and n = 14). Afterwards we analyzed cor-
relation of the obtained autoantibody titers with clinical parameters for each patient. Our
results prove that using novel antigens clinically relevant autoantibodies can be detected
with high repeatability, sensitivity and specificity. Unlike previously used antigens the
obtained autoantibody titers strongly correlate with high disease activity and in particular,
with arthritis, renal involvement, anti-Smith antibodies and high lymphocyte count. Impor-
tantly, chemical composition of antigens has a strong influence on the correlation of
detected autoantibodies with disease activity and manifestations. This confirms the crucial
importance of antigens’ composition on research and diagnostic assays, and opens up
exciting perspectives for synthetic antigens in future studies of autoimmunity.
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Introduction
Autoimmune diseases are very diverse and abundant (>80), and they are in general character-
ized by production of antibodies against one’s own biomolecules and tissues [1]. The causes of
autoimmune disease are not fully understood [1]. However, several conditions are character-
ized early on by production of autoimmune antibodies (autoantibodies) against cellular phos-
pholipids and phospholipid-protein conjugates [2]. At present, only the first type of
autoantibodies are investigated, but the latter could also become a valuable biomarker in diag-
nosis and monitoring of autoimmune diseases, including antiphospholipid antibody syndrome
(APS) and systemic lupus erythematosus (SLE). Multiple reports confirm high clinical rele-
vance of autoantibodies towards phospholipid-protein complexes but not towards phospholip-
ids alone [3]. This is due to the fact that autoantibodies do not recognize a phospholipid itself
but its complex with numerous plasma proteins [3]. Examples include autoantibodies pro-
duced against non-covalent complexes of the phospholipids cardiolipin and phosphoethanola-
mine with β2-glycoprotein I (β2GPI) and prothrombin. These autoantibodies are hallmarks of
APS and are also observed in patients with SLE and autoimmune neurological diseases [3,4]. If
not early diagnosed and treated, these conditions can cause serious health complications and
even death [5].
The incidence of SLE in the general US population is approximately one in 2000, with a
nine-to-one female gender prevalence, occurring mostly in non-Caucasian subjects [6]. How-
ever, there are still no definite diagnostic criteria, monitoring approaches or treatments. In par-
ticular, SLE patients are very diverse with respect to disease manifestations and clinical
parameters, which have to be taken into account [7]. Therefore, reliable autoantibody tests
with synthetic antigens could become an important component of diagnostics, research and
point-of-care monitoring of autoimmune diseases.
Multiple reports confirm biological activity of phospholipid-protein complexes and their
role in autoimmunity. However, most diagnostic assays have applied lipids and corresponding
proteins separately (Fig 1) [8], because synthesis of conjugates with well-defined structure and
purity was previously unachievable. Moreover, phospholipid−autoantibody binding is highly
sensitive to the assay conditions including temperature of incubation and exposure to light [8–
10]. These factors likely contribute to low reproducibility in assays and to weak correlation of
the results with clinical manifestations of the disease. Applying lipids and proteins as separate
antigens is due to the previously unachievable synthesis of synthetic conjugates with well-
defined structure and purity. Indeed, lipidation of proteins is a challenging chemical process,
which potentially can result in low yields and insufficient purity of products [9]. Recent prog-
ress in bioconjugation, including the development of copper-catalyzed azide-alkyne cycloaddi-
tion, or CuAAC click chemistry, opens up an exciting opportunity to create such reagents
using synthetic biomolecules [11]. Advantages of the synthetic antigens compared to natural
analogues are high chemical and biological stability, purity and well defined chemical structure
of the bioconjugation products [11]. Recently, we proved high efficacy of the CuAAC approach
for the synthesis of phosphoethanolamine conjugates with prothrombin and β2GPI [9]. How-
ever, attempts to attach oxidized cardiolipin 7 to same proteins resulted in low yields and low
biologic activity of products (Fig 1, compounds 4–6). Clearly, the conditions of oxidation for
cardiolipin have to be optimized in order to obtain desired antigens in high yields [9].
Cross-reactivity of autoantibodies is another obstacle to their utilization as biomarkers for
autoimmune conditions [9]. Low specificity results in low reliability of tests and limits their
usefulness in diagnostics and understanding autoimmune diseases [9,12,13]. In particular,
cross-reactivity with nucleic acids and other proteins has been reported [9,12]. We hypothesize
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that this is caused by high heterogeneity of currently applied antigens, absence of complemen-
tary protein within the molecular structure and low chemical stability.
In this paper, we introduce novel synthetic antigens, cardiolipin-β2GPI and cardiolipin-pro-
thrombin, and prove their utility in diagnostics of autoantibodies. Novel antigens reported
herein are prepared by convenient click chemistry approach in high yields and purity. Tests of
specificity against human monoclonal antibodies prove our hypothesis of improved specificity
as a result of conjugating biologically complementary molecules in a regioselective fashion.
The developed synthetic conditions take into account the following challenges of protein lipi-
dation: 1) sensitivity of lipids to oxidation; 2) high affinity of lipids to plastic; 3) steric hin-
drance of lipids and proteins which decreases cross-coupling yields. Next, we show the utility
of the prepared phospholipid-protein conjugates in enzyme-linked immunosorbent assay
Fig 1. Chemical structures of previously reported antigens and newmolecules. Previously, cardiolipin was subjected to harsh oxidation prior to
coupling to protein cargos via amide bond (compounds 4–6). Herein, linker between cardiolipin and proteins has been increased, and biologically
complementary prothrombin and β2GPI were attached to azide 13 under mild conditions.
doi:10.1371/journal.pone.0156125.g001
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(ELISA) using two different cohorts of patient samples and healthy controls. Finally, we inves-
tigate correlation of the observed autoantibodies with multiple clinical parameters and verify
the causal effect of several disease manifestations on the elevated autoantibody titers.
Materials and Methods
18:1 cardiolipin 1 (1ʹ,3ʹ-bis[1,2-dioleoyl-sn-glycero-3-phospho]-sn-glycerol (sodium salt)) and
phosphoethanolamine azide 12 (distearoyl-sn-glycero-3-phosphoethanolamine-N-[azido
(polyethulene glycol)-2000] (ammonium salt)) were purchased and used as received from
Avanti Polar Lipids. β2-Glycoprotein I (β2GPI) and prothrombin were obtained from Diarect
Antigens and Sigma. Pentynoic sulfotetrafluorophenyl (STP) ester, 3-azidopropan-1-amine,
reagents and solvents for click chemistry were provided by Lumiprobe. Other reagents, buffers
and solvents were obtained from Sigma Aldrich and used without additional purification. Syn-
thesis of azide 13 and conjugation to proteins is described in S2 Appendix.
All the reactions involving phospholipids and storage of their conjugates with proteins were
performed in glass vials and in dark. 96-well Maxisorb NUNC microplates for ELISA assays
were purchased from Thermo Fisher Scientific.
Human monoclonal antibodies used as controls for unspecific binding were purchased
from NIH AIDS Reagent Programme (a-p24, a-gp41) or provided by Stanford University (B12;
produced in Mellins lab) [14,15]. Catalogue numbers: a-p24, 530; a-gp41, 531. Host species for
the antibodies were humans. Antigens used to raise and test antibodies: p24, gp41 and gp120.
Final antibody dilution was 1:10.000. Each antibody in a dilution 1:10.000 was validated by
indirect ELISA assay with corresponding antigen: p24, gp41 and gp120.
Bradford assay was performed following manufacturers protocol using standard reagents
(BioRad) [16].
Human samples were obtained from Immunovision, USA (HNP: human normal plasma
from a healthy adult patient, HCL: human disease stated plasma from a patient diagnosed with
APS), Stanford University Hospital, Stanford, CA, USA (sera, SLE subjects and matched
healthy controls), and Odense University Hospital, Odense, Denmark (plasma). Several
patients at Stanford University Hospital provided multiple samples in different time points.
This resulted in a total number of 40 and 16 samples for SLE and healthy controls, respectively.
The samples were characterized by clinical data, common serological biomarkers, treatment
intensity and diseases activity stage. Samples were obtained under IRB approved protocols.
Written approval by The Danish Data Protection Agency was obtained in November 2015.
Committee of Information Safety of the Region Southern Denmark at the Danish Data Protec-
tion Agency specifically approved the whole study (permission signed by Pernille Winther
Christensen).
Age, gender, race and ethnicity of subjects have an influence on the origins and outcome of
autoimmune diseases and therefore were determined after the establishment of diagnosis. This
was done following National Institutes of Health (NIH) guidelines and taking into account
most relevant grouping to studies of autoimmune diseases [6]. Based on previous literature,
groups were formed as follows: male/female; age at diagnosis/age at sample collection; Hispanic
and non-Hispanic; White, Black, Asian, and Hawaiian/Pacific Islander.
No additional rules for human categorization were required by funding agency. Confound-
ing variables such as socioeconomic status, nutrition, environmental exposures were not used
in this study. Further details on characterization of patient samples are given in S3 Appendix.
ELISA assays, reproducibility analysis and testing the stability of antigens were carried out
as described before [9]. Initially, background signal of each sample was tested to be below A450
0.06 using non-coated microplates upon blocking at the same conditions as for the original
Phospholipid-Protein Conjugates
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experiment. To determine equilibrium time for the antigen binding, pre-coated microplates
were subjected to incubation with samples in dilution 1:200 over a time course of 40 min– 3
hrs. Secondary incubation was always carried out for 1 h at room temperature using 1:35.000
dilution of corresponding HRP-conjugate. Results of this assay are presented in the S2
Appendix.
Linear range for each antigen was determined by testing series of control dilutions (HNP,
HCL in dilutions 1:50 to 1:2000). According to the results dilutions 1:100–1:750 were within
the linear range of assay for each antigen (R2> 0.97). For the controls and patient samples,
weak positive (+/-) and positive (+) signal were determined as 2- and 3-fold signal, respectively,
above the mean value for a healthy control cohort (n = 14) [17].
For the dose response assay, 8 samples (30%, Stanford University Hospital SLE cohort) were
randomly selected. Next, for each applied antigen, absorbance (A450) values were determined
by ELISA in 1:100 serum dilutions and converted to U/mL values equation dividing the
obtained absorbance at 450 nm to the total sample protein (in g/mL).
Having done this, dilution of each serum was normalized to fit the following titration (Unit/
mL 10−3): 0.04, 0.07, 0.11, 1.5, 2.9, 4.5 and 6.7. Finally, ELISA assay was repeated for each anti-
gen using selected sera and these 7 dilutions.
For statistical analysis, the following clinical parameters of each patient were considered:
age (at onset and at sample date), gender, ethnicity, race, diagnosis, disease activity (at onset
and at sample date), clinical manifestations, patient’s complaints, and applied medications
which are known to induce autoantibodies (see S3 Appendix). The latter formed eight groups:
corticosteroids, hydroxychloroquine, atorvastin, simvastin, corticosteroids+hydroxychloro-
quine; hydroxychloroquine+atorvastin, atorvastin+simvastin; corticosteroids+simvastin. Dif-
ferences were analyzed for statistical significance with multiple regressions (ordinary least
squares (OLS) analysis) in Stata [18]. Groups were compared for difference in means of anti-
body titers using ANOVA. Holm–Bonferroni method was used to counteract the problem of
multiple comparisons [18]. A p-value (regular/adjusted) of less than 0.05 was considered sig-
nificant for each correlation. Statistical power of the corrected test for diverse medication
(eight comparisons in total) was estimated to be 77% for a total sample size 74 and anticipated
effect size 0.2 (calculated in Stata) [19].
Results
Synthesis of novel antigens
Initially, we selected cardiolipin-β2GPI and cardiolipin-PT as target molecules for this study,
owing to their documented biological activity and relevance to SLE and APS (Fig 1) [4,9]. Pre-
viously, we and others have reported synthesis of phospholipid-protein conjugates using oxi-
dized cardiolipin RCOOH [9]. Product carboxylic acid was used for coupling with amino
groups of proteins yielding antigens 4–6 (S2 Appendix) [9]. However, we observed low efficacy
of coupling when mono-oxidized cardiolipin 7 reacted directly with BSA, prothrombin and
β2GPI (yields 52–68%). In contrast, using commercially available PEGylated phosphoethano-
lamine-azide, antigens 8, 10 could be prepared in high yields (Fig 1) [9].
In this study, we adjusted conditions for cardiolipin oxidation. We also extended length of a
linker for the attachment of cardiolipin to proteins (Fig 1). In addition, phosphoethanolamine
modified prothrombin and β2GPI antigens 5,6 were prepared (Fig 1). Chemical composition
of product antigens was verified by gel electrophoresis and MALDI MS spectra (see S2 Appen-
dix). According to MS data, 10–11 and 12–13 cardiolipin residues were attached to β2GPI and
prothrombin, respectively. This is significantly higher than for a previous approach using
Phospholipid-Protein Conjugates
PLOS ONE | DOI:10.1371/journal.pone.0156125 June 3, 2016 5 / 16
direct coupling of cardiolipin derivative 7 to proteins (1–2 residues) [9], and might be a result
of reduced steric hindrance of the cardiolipin reagent 13 by the extended linker [20].
Improved binding specificity for new phospholipid-protein conjugates vs.
controls
Our next goal was to evaluate the hypothesis that cross-linking biologically complementary
phospholipids and proteins in a chemically efficient way would decrease unspecific binding of
the resulting antigens. To do this, we carried out series of IgG ELISA assays using human
monoclonal antibodies against HIV-1 antigens [14] and polyclonal healthy control sera
obtained at Stanford University Hospital (n = 14) and from Immunovision (HNP) [15].
The results of IgG class ELISA for novel antigens and controls obtained using monoclonal
antibodies towards HIV-1 antigens and healthy sera samples are shown in Table 1. We
observed the highest level of unspecific binding for non-covalent complexes of phospholipids
and proteins 1+2 and 1+3. In contrast, cross-linked conjugates 8–11 showed only low to no
non-specific binding in similar experiments (for example, Table 1, data for 11 compared to 1
+2 and 1+3). Conjugates 8–10 demonstrated a weak binding to anti-gp41, whereas binding to
anti-p24 and B12 antibodies completely disappeared upon conjugation of phospholipid with
protein. High reactivity on HIV-1 specific monoclonal antibodies and healthy control sera
observed for mixed phospholipid-protein controls could result from the high heterogeneity of
non-covalent structures leading to unspecific interactions with polyclonal antibodies. In turn,
cross-reactivity of antigens 8,10might be caused by the presence of PEG linker [21]. Alterna-
tive linker design for the attachment of phosphoethanolamine to proteins is an objective of our
on-going research and will be published in the near future. Finally, the most specific antigens
9,11 were further applied in the studies of human samples described below.
Autoantibody detection in patient samples
The initial ELISA assay was performed manually using microtiter plates coated with antigens
8–11 or control antigens [8,9]. Sample titration experiments showed low response of IgM
Table 1. Analysis of binding specificity for cross-linked antigens 8–11 and controls 1–3,12.a
Antigen No/details Binding human monoclonal
antibodies:
Response in healthy controls, Stanford University Hospital, HNP (% of samples)
a-p24 a-gp41 B12
8/PEPEG-PT - + - +/- (12%)
10/PEPEG-β2GPI - +/- - + (6%), +/- (12%)
9/CL-PT - +/- - +/- (6%)
11/CL-β2GPI - - - - (100%)
2/β2GPI - +/- - +/- (25%)
3/PT +/- - +/- +/- (25%)
1+2/CL + -β2GPI +/- +/- +/- + (44%), +/- (25%)
1+3/CL + PT +/- +/- + + (25%), +/- (25%)
2+12/PEPEG+β2GPI +/- +/- + + (25%), +/- (12%)
3+12/PEPEG+β2GPI +/- +/- + + (25%), +/- (25%)
a Weak positive (+/-) and positive (+) signal were deﬁned as 2- and 3-fold absorbance signals, respectively, above the mean value for a healthy control
group. PEPEG, PT, CL, β2GPI are PEGylated phosphoethanolamine, prothrombin, cardiolipin and β2-glycoprotein I, respectively. For chemical structures
of antigens and controls, see Fig 1.
doi:10.1371/journal.pone.0156125.t001
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antibodies to the dilution, whereas IgG antibodies showed reduced signal upon dilution with a
high degree of linearity (R2> 0.95; S2 Appendix). Therefore, in this work we focused on the
IgG assay. In addition, repeatability of assays, along with stability of new antigens and controls
were studied as described before. Our data proves that new antigens have superior levels com-
pared to controls in agreement with previous data (see S2 Appendix) [9].
Next, healthy patients (n = 14) and a cohort of pediatric SLE patients (n = 27), both moni-
tored at Stanford University Hospital, were analyzed. Prior to the studies, total protein concen-
tration in each sample was analyzed by Bradford assay [16]. Having corrected dilution of each
sample to the same total protein value, ELISA experiments were performed as we described
before [9]. According to our data, binding equilibrium for the autoantibodies in the samples
was achieved within 1 h incubation at room temperature (S2 Appendix). Cut-off value for each
applied antigen was established as 2- and 3-times mean A450 value for healthy patients for the
weak positive and positive signal, respectively [17].
Studies of the SLE cohort obtained from Stanford University Hospital under these condi-
tions identified five and seven positive patients (19% and 26%) when antigens 9 and 11 were
applied. This was in contrast with nine and three positive patients (33% and 11%) detected
using β2GPI and mixed antigen cardiolipin+β2GPI, respectively. Using clinical anti-phospho-
lipid test, 7 positive patients were identified (Table 2).
To get further insight into the nature of detected autoantibodies, their dose-response pro-
files were obtained (Fig 2) [22]. As can be seen from the resulting profiles, 9,11 and control
proteins showed different dose response curves for autoantibodies to phospholipid-protein
conjugates. Antigens 9 and 11 displayed much sharper saturation curves than β2GPI and its
mixture with cardiolipin. Notably, β2GPI showed lowest saturation value among all studied
antigens, whereas the highest dispersity among positive samples was observed for antigen 11.
Overall, altered dose-response curves suggested different concentrations and/or autoantibody
repertoire detected for antigens 9,11 than those for β2GPI and cardiolipin mixture with β2GPI.
Table 2. Clinical data and results of analyses of the Stanford University Hospital SLE subjects used in this study.*
Clinical parameter: SLE samples (Stanford University Hospital)
9 (+) 9 (-) 11 (+) 11 (-) aPL + clinical aPL—clinical
N (subjects) 5 22 7 20 7 20
Female/Male 5/0 18/4 7/0 16/4 7/0 16/4
MDO age (yr) (range) 12 (7–16) 15 (9–17) 12 (10–16) 15 (7–17) 12 (10–16) 15 (7–17)
MSC age (yr) (range) 12 (7–16) 15 (9–19) 12 (10–16) 15 (7–19) 12 (10–16) 15 (7–19)
Median SLE-DAI (range) 10 (6–30) 6 (0–30) 7 (6–30) 6 (0–30) 7 (4–17) 10 (0–30)
Positive Clinical aPL test (%) 40 22 57 15 - -
ANA positive status (%) 100 100 100 100 100 100
Anti-Smith positive (%) 80 27 57 30 28 40
Renal/total no. samples (%) 60 36 57 35 28 45
CNS/total no. samples (%) 0 0 0 0 0 0
Malar/total no. samples (%) 80 54 71 50 71 50
Lupus anticoagulant/ total no. samples 0 5 0 5 2 3
Mean absolute lymphocyte count (ALC) 5400 1200 4050 1100 2100 1250
Medication G1 G1 G2 G1 G1 G1
* MDO = median age at disease onset, MSC = median age at sample collection, PL = phospholipid; Medication group 1 (G1): Pred = prednisone,
HCQ = hydroxychloroquine, ST = other steroids, N = naproxen, SO = solumedrol, CY = cytoxan; G2 medication = G1 –other steroids.
doi:10.1371/journal.pone.0156125.t002
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As a result, we also expected different correlation of the observed autoantibody titers with clini-
cal parameters of the analyzed patients.
Robustness and clinical relevance of the new antigens was further evaluated by the analysis
of blood samples from adult patients obtained from Odense University Hospital, Denmark.
The assay was performed using similar plate coating, incubation conditions and cut-off values
as for SUH cohort, although in a fully automated regimen. The results were compared to com-
mercial anti-cardiolipin and anti-β2GPI tests (Euro Diagnostica), which were performed for
Odense University Hospital patients under similar conditions. Summarized ELISA results for
healthy controls (Stanford University Hospital) and two patient cohorts (Stanford University
Hospital SLE subjects and Odense University Hospital patients) are shown in Fig 3. As can be
seen, the background signal of healthy controls was highest for cardiolipin 1, prothrombin and
Fig 2. Dose-response profiles for SLE sera samples, obtained using antigens 9,11 (A-B), β2GPI (C) andmixture of β2GPI with cardiolipin (D). IgG
assay was carried out under the developed indirect ELISA conditions, using randomly selected 16 sera samples (Stanford University SLE cohort), and similar
coating and incubation conditions for all antigens. Concentration of autoantibody for the titration in each sample was normalized as a ratio of absorbance
using corresponding antigen to total protein in the sample (see Materials and Methods for details).
doi:10.1371/journal.pone.0156125.g002
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mixture of phosphoethanolamine with prothrombin. Stanford University Hospital SLE sam-
ples showed higher autoantibody titers than the Odense University Hospital cohort, especially
when antigen 11 and mixed antigen cardiolipin+β2GPI were applied. Notably, positive samples
indicated by 9,11 dramatically varied from those indicated by separated antigens. Group analy-
sis using ANOVA confirmed a statistically significant difference between the groups within
Stanford University Hospital SLE and Odense University Hospital cohorts with a p value
below 0.01 (see Materials and Methods).
Clinical parameters of the studied SLE patients and their autoantibody titers are summa-
rized in Table 2. Notably, similar number of subjects showed presence of antibodies against
9,11 compared to clinical test. However, there was no overlap between the patients positive
according to clinical anti-phospholipid tests and the developed assay. Next, lupus anticoagu-
lant was positive only for patients with elevated titers of anti-β2GPIs and some patients with
clinically determined positivity, but not antibodies binding to 9,11. On the contrary, median
value of absolute lymphocyte count (ALC) was elevated for the patients who had autoantibod-
ies binding to 9 and 11, but not other tested antigens.
Interestingly, 57% and 80% of positive patients detected using phospholipid-protein conju-
gates were also anti-Smith positive, which is a highly specific antibody for non-drug induced
SLE [4,23]. Correlation (p = 0.002) was confirmed by OLS test (Fig 4) [18]. This is in contrast
to only 28% and 11% anti-Smith positive samples indicated by clinical test and controls used in
this study. Furthermore, 71% and 80% of patients having antibodies to phospholipid-protein
conjugates had malar rash and 57–60% were diagnosed with arthritis and SLE nephritis (vs.
15–28%. according to clinical anti-phospholipid test). Overall, median disease activity index
(SLE-DAI) [24] was similar for positive samples detected using antigens 9 and 11. However,
antigen 9 detected autoantibodies in patients with slightly more active SLE than 11 (median
SLE-DAI 10 vs 7).
Demographic and clinical parameters of Odense University Hospital patients significantly
varied from the Stanford University SLE cohort and between each other (Table 3 and S3
Appendix). In general, the former group was not studied in as much detail as the latter. Median
age at diagnosis and age at sample was much older for Odense University Hospital cohort (50
Fig 3. Absorbance values obtained by IgG ELISA assay. The assay was carried out using control antigens, 8–11, and three cohorts of subjects: adults at
Odense University Hospital (n = 34), SLE patients at Stanford University Hospital (n = 27), and healthy controls (Stanford University Hospital; n = 14).
CL = cardiolipin; PT = prothrombin; PE = phosphoethanolamine.
doi:10.1371/journal.pone.0156125.g003
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vs. 14). Next, no diagnosis was established for 48% of patients, although 90% of them had man-
ifestations of autoimmune conditions and 17 (50%) took no medication prior to sample collec-
tion. In Odense University Hospital samples, we observed almost complete overlap of positive
results for conjugates 9 and 11 (Table 3). Notably, using antigen 9 in the assay gave lower signal
(in a weak positive range only), whereas antigen 11 provided high signal. As in Stanford Uni-
versity Hospital SLE samples, we observed low to no overlap with the results of clinical anti-
phospholipid/anti-β2GPI tests.
Fig 4. Representative statistical analysis of the data obtained for new antigens.Observed correlations between antibodies to antigen 11 (A450) and
anti-Smith results for disease stated patients (Stanford University Hospital SLE cohort): data plot (A) and linear regression plot (B).
doi:10.1371/journal.pone.0156125.g004
Table 3. Clinical data and results of Odense University Hospital patients showing positivity to phospholipid-protein conjugates.*
Patient nr. Diagnosis Manifestations Binding antigen: Serology Medication
9 11 cardiolipin β2GPI
P3 Venous thromboembolism,
spinal stenosis, hyperlipidemia
Lumbal pain,
pulmonary embolism
+ - - + None Xarelto, Atorvastatin,
Gabapentin
P6 Hepatocellulary carcinoma Stomach pain, lumbal
pain
+ ++
+
++ - None None
P8 Urticarial vasculitis Skin itch,
thrombocytopenia
+ ++ - ++ ANA+ Dapson
P12 None Sclerotic aortic valve,
TCI symptoms
+ ++ - + None Lercanidipin,
Atorvastatin,
Clopidogrel, Losartan
P15 None None + ++ ++ - None None
P20 SLE Arthritis, nephritis,
cerebral apoplexia
- ++
+
- ++ ANA+, a-
dsDNA+
Marevan Plendil
Simvastatin
Remai-ning
cohort, 28
subjects
SLE (15%), Other (27%), None
(48%)
diverse - - + (22%) +
(11%)
ANA+ (21%);
un-speciﬁed
As above (56%); None
(44%)
* Drugs potentially causing SLE are indicated in bold italics.
doi:10.1371/journal.pone.0156125.t003
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Notably, using separated tests on cardiolipin and β2GPI, either anti-cardiolipin or a-β2GPI
positivity has been observed for particular patients. Elevated anti-cardiolipin titers mostly asso-
ciated with not diagnosed patients who had diverse manifestations of autoimmune conditions
(Table 3). On the contrary, high a-β2GPI titers correlated mostly with thrombosis and SLE.
Elevated anti-prothrombin titers showed no correlation with any particular disease manifesta-
tions (data not shown). In turn, positivity using conjugate 9 correlated with thrombosis and
sclerotic manifestations, but not with adult SLE. At last, conjugate 11 provided positivity which
associated strongest with renal (kidney) SLE and arthritis.
As a next aspect, we analyzed medical records for Stanford University Hospital SLE and
Odense University Hospital patients with respect to medication use. The data were divided
into four groups containing one or more medications that are known to induce autoantibodies
[25–28], and subjected to statistical analysis. Using OLS tests with and without interaction
between variables (eight interactions in total), we confirmed no correlation between a particu-
lar medication or a group of medications and elevated titers of autoantibodies to phospholipid-
protein conjugates (p> 0.05 with a statistical power 77% for a total of 74 samples).
Finally, we studied repeatability of the developed assay and chemical stability of novel anti-
gens (see Materials and Methods). Our assay was highly reproducible with absorbance values
varying within 0.5–0.8 of mean titer for each independent analysis. Moreover, antigens 9,11
were stable for up to 3 months at +4°C in glass vials and on the surface of microtiter plates, and
up to 1 year in glass vials at -20°C. This is in contrast to cardiolipin which degraded after
approx. 3 weeks of storage at +4°C in a glass vial or on the microtiter plate, and after 3 months
of storage in a vial at -20°C.
Discussion
Since 1990s there has been growing evidence on clinical relevance of autoantibodies against
plasma proteins binding phospholipids [29–32]. However, role of phospholipids themselves in
the autoantibody recognition remained unclear. Separate application of biologically comple-
mentary phospholipids and plasma proteins lead to low clinical relevance of detected autoanti-
bodies [30–32]. Moreover, chemical heterogeneity of typically applied antigens extracted from
natural sources, their low stability and therefore poor reproducibility of the available assays
might contribute to current disagreement between tests [13]. In this study our main goal was
to specifically detect clinically important autoantibodies using novel, reliable reagents. We also
aimed at contributing to the improved understanding of the correlation between autoantibody
titers and the clinical features of a broad range of autoimmune diseases where these antibodies
are present.
Synthesis of covalently linked phospholipid-protein conjugates represents a challenging
task due to high hydrophobicity of the lipids, their low solubility in aqueous media, instability
and low reactivity. Previously, we and others aimed at synthesis of phospholipid-protein conju-
gates using coupling reactions and click chemistry [9,10]. The latter approach has proved to be
more attractive, giving high yields of the phosphoethanolamine derivatives 8,10 (Fig 1, 88%
and 92%). In this work, we demonstrated that decreasing steric hindrance for cardiolipin using
increased linker length provides better coupling yields with protein molecules (9,11, 89% and
84% vs. 4–6 [9], 54–66%, respectively). Simultaneously, regioselective attachment to proteins
by click chemistry could be performed using novel azide 13 (Fig 1).
Having synthesized cardiolipin containing antigens and phosphoethanolamine controls, we
evaluated their binding of anti-HIV monoclonal antibodies (B12, a-p21 and a-gp41) and poly-
clonal antibodies in healthy human controls [29,30]. Previously, we demonstrated high cross-
reactivity of anti-phospholipid antibodies on ss and dsDNA [9]. However, this type of cross-
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reactivity might be caused by shared antigenic determinant for antibodies to phospholipid-pro-
tein complexes and aDNAs which is important for their function [3]. Therefore we selected
human monoclonal antibodies against different antigens as controls. As can be seen in Table 1,
novel antigens showed lower unspecific binding then reference antigens. This is one of the
most important results of this paper, because it shows that the binding specificity of phospho-
lipid antigens can be improved by their cross-linking with biologically complementary
proteins.
The next important aspect of this work is investigation of autoantibodies in two different
cohorts of human patients: children diagnosed with SLE in USA and adults in Denmark (Stan-
ford University Hospital SLE and Odense University Hospital cohorts, respectively). We con-
sidered multiple clinical parameters when selecting these patients. Thus, in Stanford University
Hospital SLE patients (n = 27), the diagnosis SLE was already established approx. 1 year before
sample collection (S3 Appendix). Treatment of these patients included simultaneous applica-
tion of various medications (see Table 1). In contrast, Odense University Hospital patients
were older; 48% of them had no diagnosis and were not treated prior to sampling. The remain-
ing 42% of Odense University Hospital patients had diverse diagnoses and manifestations of
autoimmune conditions (Table 3 and S3 Appendix).
IgG class ELISA studies of the patients provided us with the following information on auto-
antibodies to phospholipid-protein conjugates: 1) binding equilibrium was achieved for all
patients within the same incubation time (approx. 1 h, see Materials and Methods); 2) novel
antigens showed less non-specific binding and different dose-response curves compared to sep-
arated phospholipid and protein antigens; 3) overlapping autoantibody profiles were detected
for both cardiolipin-β2GPI and cardiolipin-prothrombin; 4) there is a significant disagreement
between currently applied tests and the results provided using new antigens One possible
explanation of the different dose-response profiles in patient samples could be different affinity
of the detected autoantibodies [22]. We also speculate that antibodies detected by novel anti-
gens could be produced under different clinical circumstances (disease states) than those bind-
ing to individual phospholipids and proteins that are used in current tests [8–10,29]. This also
could explain different associations between autoantibodies and clinical parameters observed
when individual antigen components were applied. Overall, our results experimentally demon-
strate statistically significant differences in autoantibody repertoires targeting chemically dif-
ferent antigens.
Previously, antibodies against β2GPI in lupus anticoagulant positive samples were suggested
as a biomarker of thrombosis in SLE and APS patients [29]. Indeed, we observed higher lupus
anticoagulant activity in patients with positive titers of a-β2GPI when β2GPI is used alone
(50%). Most likely due to efficient preventive treatment, thrombolytic events occurred only in
2 (3%) patients used in our study. According to the literature, other a-β2GPI positive patients
with lupus anticoagulant positive tests still form a group of risk for thrombosis [29–31]. In
turn, positivity using antigen 9 observed in this study (Table 3, patient P3) is a new aspect of
predicting thrombosis which might bring additional insights into the disease.
In general, our findings indicate high prognostic and scientific potential of cross-linked
phospholipid-protein conjugates. This includes strong correlation of elevated autoantibody
titers with high disease activity and in particular with arthritis and renal (kidney) disease, anti-
Smith positivity and high absolute lymphocyte count levels. Arthritis and renal disease are
common in SLE [33–35]. In turn, anti-Smith antibody is a very specific type of antinuclear
antibody which in SLE is associated with central nervous system involvement, kidney disease,
lung fibrosis and pericarditis [23,36]. At last, high absolute lymphocyte count (above 5000) is
known to be a biomarker of on-going (chronic) inflammation, infections and cancer of the
blood or lymphatic system [37]. Recently it was also shown that absolute lymphocyte count
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values correlates with cancer outcome [37]. Based on this data, positivity using antigens 9,11
could contribute positively to diagnosis of high risk profiles in diverse groups of patients having
autoimmune diseases.
Subjects selected for this study received medication that could result in a drug-induced SLE
and increased titers of autoantibodies (corticosteroids, hydroxychloroquine, cholesterol-lowering
atorvastin, simvastin, and combinations thereof; see Tables 2 and 3) [25–29]. Having investigated
treatment details for the patients by OLS followed by Holm–Bonferroni correction for multiple
comparisons, we concluded that there was no statistically significant correlation between a partic-
ular treatment and observed autoantibody titers (adjusted p> 0.05) [19]. The number of data
points for this study is relatively small (74 samples were obtained from 61 patients, see S3 Appen-
dix). Nevertheless, our data suggests that with a statistical power of 77% the novel antigens pre-
pared herein allow for the detection of not drug-induced autoantibodies [19].
Finally, according to our studies novel conjugates show higher reproducibility and stability
than currently available antigens and have advantage of straightforward synthetic route, high
chemical homogeneity and decreased cross-reactivity on nonspecific human antibodies
(Table 1; Materials and Methods).
In conclusion, this work describes a robust synthetic route leading to efficient phospho-
lipid-protein antigens for the detection of human autoimmune antibodies. To achieve neces-
sary specificity and sensitivity of autoantibody detection, we cross-linked biologically
complementary phospholipids and proteins under mild, effective conditions. In doing this, we
found it necessary to extend the linker between sterically hindered cardiolipin and proteins for
further conjugation by click chemistry. This approach is not limited to cardiolipin-β2GPI and
cardiolipin-prothrombin conjugates, but can be potentially expanded to other clinically rele-
vant antigens, such as derivatives of sphingomyelin, ethanolamine etc. [38–40] As we prove in
this work, the cross-linked phospholipid-protein conjugates have advantages of high specificity
towards autoantibodies in human samples. Moreover, detected autoantibodies may also play a
role in pathogenesis of various autoimmune diseases. Successfully demonstrated as a proof-of-
principle in two cohorts of patients diagnosed or having manifestations of autoimmune dis-
eases (Stanford University Hospital SLE cohort, n = 27, and Odense University Hospital
patients, n = 34), this method can be applied to detect antibodies to phospholipid-protein com-
plexes in other autoimmune conditions. In particular, these autoantibodies are of high rele-
vance in neurological autoimmunity, e.g. autoimmune demyelination conditions leading to
multiple sclerosis and other diseases [41,42]. Reliable synthetic antigens could yield new
insights into the pathogenesis of these diseases and simultaneously serve as a simple, reliable
method for research, diagnosis, prognosis and point-of-care monitoring of patients.
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